These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25940443)

  • 1. [Huntington's disease].
    Rollnik JD
    Nervenarzt; 2015 Jun; 86(6):725-35. PubMed ID: 25940443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
    Essa MM; Moghadas M; Ba-Omar T; Walid Qoronfleh M; Guillemin GJ; Manivasagam T; Justin-Thenmozhi A; Ray B; Bhat A; Chidambaram SB; Fernandes AJ; Song BJ; Akbar M
    Neurotox Res; 2019 Apr; 35(3):739-774. PubMed ID: 30632085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for neuroprotective therapies in prodromal Huntington's disease.
    Chandra A; Johri A; Beal MF
    Mov Disord; 2014 Mar; 29(3):285-93. PubMed ID: 24573776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hope for Huntington's disease patients: first clinical gene silencing study in progress].
    Rollnik JD
    Fortschr Neurol Psychiatr; 2017 Aug; 85(8):463-466. PubMed ID: 28841744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids: novel medicines for the treatment of Huntington's disease.
    Sagredo O; Pazos MR; Valdeolivas S; Fernandez-Ruiz J
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):41-8. PubMed ID: 22280340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Huntington's Disease: Relationship Between Phenotype and Genotype.
    Sun YM; Zhang YB; Wu ZY
    Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiglutamate therapies in Huntington's disease.
    Kieburtz K
    J Neural Transm Suppl; 1999; 55():97-102. PubMed ID: 10335496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the pharmacological management of Huntington's disease.
    Frank S; Jankovic J
    Drugs; 2010 Mar; 70(5):561-71. PubMed ID: 20329804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic modifiers of Huntington's disease.
    Gusella JF; MacDonald ME; Lee JM
    Mov Disord; 2014 Sep; 29(11):1359-65. PubMed ID: 25154728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is Huntington's disease a neurological or psychiatric disorder? case report].
    Dubas-Slemp H; Tylec A; Michałowska-Marmurowska H; Spychalska K
    Psychiatr Pol; 2012; 46(5):915-22. PubMed ID: 23394029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational agents for the management of Huntington's disease.
    Müller T
    Expert Opin Investig Drugs; 2017 Feb; 26(2):175-185. PubMed ID: 27927041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
    Squitieri F; de Yebenes JG
    Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidants in Huntington's disease.
    Johri A; Beal MF
    Biochim Biophys Acta; 2012 May; 1822(5):664-74. PubMed ID: 22138129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foundation-directed therapeutic development in Huntington's disease.
    Dominguez C; Munoz-Sanjuan I
    J Med Chem; 2014 Jul; 57(13):5479-88. PubMed ID: 24432836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: an update of therapeutic strategies.
    Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
    Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene silencing approaches for the treatment of Huntington's disease].
    Merienne N; Déglon N
    Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.